Enabling glycan biomarker detection & analysis

Glycosensors and Diagnostics, LLC (G&D) is commercializing enabling technologies for applications in glycoscience. G&D’s Lectenz® reagents are engineered with high affinity and specificity for glycan structures of interest. G&D is also translating its Lectenz® technology into an easy-to-use application platform called GlycoSense™ for glycan detection and analysis in applications such as disease biomarker detection and bioprocessing of biologics and biosimilars.


Dr. Kausar N. Samli (CEO) receives Georgia Bio's 2016 Emerging Leader of the Year award.

G&D participates in 2015-2016 Advanced Commercialization Track in the NIH Commercialization Accelerator Program.

G&D presents as part of the Bioscience Company Showcase at the 2015 Georgia Bio Innovation Summit.

G&D exhibits at BIO 2015 in Philidephia as part of the State of Georgia's Pavilion.

Dr. Lori Yang (CSO) receives 2015 Amelia Earhart Innovator Award.

G&D awarded NIH STTR Phase I based on Lectenz® technology.

Dr. Kausar N. Samli (CEO) participates in panel discussion to highlight biotech growth in Georgia.

G&D participates in 2014-2015 Commercialization Training Track in the NIH Commercialization Accelerator Program.

G&D participates in I-Corps South.

Prof. Robert J. Woods (President) receives 2014 Academic Entrepreneur of the Year Award.

G&D awarded NIH STTR Phase II and SBIR Phase II based on Lectenz® technology.

G&D awarded NIH SBIR Phase I based on GlycoSense™ technology.


Open Positions:

G&D is currently hiring. See open positions in Careers.

Follow G&D: